• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Remdesivir and Kidney and Cardiovascular Outcomes in COVID-19 Patients With Reduced GFR.

作者信息

Dinulos James E, Wang Qiyu, Zhao Sophia, Cosar Duru, Seethapathy Ritu, Long Joshua D, Strohbehn Ian, Sise Meghan E

机构信息

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Analytica Now LLC, Brookline, MA.

出版信息

Kidney Med. 2024 May 3;6(7):100835. doi: 10.1016/j.xkme.2024.100835. eCollection 2024 Jul.

DOI:10.1016/j.xkme.2024.100835
PMID:38828041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11137333/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48e1/11137333/25a3ed1efcc1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48e1/11137333/25a3ed1efcc1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48e1/11137333/25a3ed1efcc1/gr1.jpg

相似文献

1
Remdesivir and Kidney and Cardiovascular Outcomes in COVID-19 Patients With Reduced GFR.瑞德西韦与肾小球滤过率降低的COVID-19患者的肾脏和心血管结局
Kidney Med. 2024 May 3;6(7):100835. doi: 10.1016/j.xkme.2024.100835. eCollection 2024 Jul.
2
Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: A retrospective multicenter study.瑞德西韦用于晚期肾病患者的新冠肺炎肺炎治疗：一项回顾性多中心研究。
Clin Infect Pract. 2022 Nov;16:100207. doi: 10.1016/j.clinpr.2022.100207. Epub 2022 Oct 13.
3
Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.瑞德西韦对 COVID-19 合并肾功能受损住院患者不良肾脏结局的影响。
PLoS One. 2023 Feb 27;18(2):e0279765. doi: 10.1371/journal.pone.0279765. eCollection 2023.
4
Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19.瑞德西韦在新冠病毒肺炎肾移植受者中的应用与安全性
Kidney Int Rep. 2021 Sep;6(9):2305-2315. doi: 10.1016/j.ekir.2021.06.023. Epub 2021 Jul 6.
5
Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19.新冠病毒肺炎住院透析患者中与瑞德西韦治疗相关的安全性及治疗结果比较
Clin Kidney J. 2022 Aug 23;15(11):2056-2062. doi: 10.1093/ckj/sfac185. eCollection 2022 Nov.
6
Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease.瑞德西韦对终末期肾病住院COVID-19患者的疗效。
World J Crit Care Med. 2022 Jan 9;11(1):48-57. doi: 10.5492/wjccm.v11.i1.48.
7
The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids.瑞德西韦与 COVID-19 患者接受类固醇治疗的院内结局的相关性。
J Antimicrob Chemother. 2021 Sep 15;76(10):2690-2696. doi: 10.1093/jac/dkab256.
8
Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.瑞德西韦及其主要代谢物 GS-441524 在治疗 COVID-19 受试者中的药代动力学的个体间变异性。
J Antimicrob Chemother. 2022 Sep 30;77(10):2683-2687. doi: 10.1093/jac/dkac234.
9
Global Cardiovascular and Renal Outcomes of Reduced GFR.肾小球滤过率降低的全球心血管和肾脏结局
J Am Soc Nephrol. 2017 Jul;28(7):2167-2179. doi: 10.1681/ASN.2016050562. Epub 2017 Apr 13.
10
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.瑞德西韦单药及联合其他药物治疗 COVID-19 的疗效和安全性：系统评价和荟萃分析。
BMC Infect Dis. 2023 Oct 9;23(1):672. doi: 10.1186/s12879-023-08525-0.

引用本文的文献

1
The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study.奈玛特韦-利托那韦对肾病患者新冠病毒病短期和长期不良结局的影响：一项倾向评分匹配研究
Open Forum Infect Dis. 2024 Dec 31;12(1):ofae756. doi: 10.1093/ofid/ofae756. eCollection 2025 Jan.

本文引用的文献

1
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.瑞德西韦治疗 COVID-19 住院患者的效果：随机对照试验的系统评价和个体患者数据荟萃分析。
Lancet Respir Med. 2023 May;11(5):453-464. doi: 10.1016/S2213-2600(22)00528-8. Epub 2023 Feb 21.
2
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.与 SARS-CoV-2 再感染相关的急性和后期后遗症。
Nat Med. 2022 Nov;28(11):2398-2405. doi: 10.1038/s41591-022-02051-3. Epub 2022 Nov 10.
3
Long-term cardiovascular outcomes of COVID-19.
COVID-19 长期心血管后果。
Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
4
Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies.COVID-19 相关的细胞性肾小球病及其他足细胞病的纵向转归。
J Am Soc Nephrol. 2021 Nov;32(11):2958-2969. doi: 10.1681/ASN.2021070931. Epub 2021 Oct 20.
5
Kidney Outcomes in Long COVID.长新冠对肾脏的影响。
J Am Soc Nephrol. 2021 Nov;32(11):2851-2862. doi: 10.1681/ASN.2021060734. Epub 2021 Sep 1.
6
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.美国重症监护病房中患有基础肾脏疾病的 COVID-19 患者的特征和结局。
Am J Kidney Dis. 2021 Feb;77(2):190-203.e1. doi: 10.1053/j.ajkd.2020.09.003. Epub 2020 Sep 19.
7
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.